Empirical antifungal therapy with an echinocandin in critically-ill patients: Prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Bruyère, Rémi ^a   Quenot, Jean Pierre ^a   Prin, Sébastien ^a   Dalle, Frédéric ^b   Vigneron, Clara ^a   Aho, Serge ^a   Leon, Cristobal ^c   Charles, Pierre Emmanuel ^a  

^a HÔPITAL DU BOCAGE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Candida sp; Candidemia; Echinocandin; Invasive candidiasis; Nosocomial infection; Sepsis

Indexed keywords

ECHINOCANDIN; FLUCONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGED; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA INCONSPICUA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CRITICALLY ILL PATIENT; FEMALE; FUNGAL COLONIZATION; HUMAN; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; CANDIDIASIS; COHORT ANALYSIS; CRITICAL ILLNESS; EVALUATION STUDY; FRANCE; PATHOLOGY; PROGRAM EVALUATION; SEVERITY OF ILLNESS INDEX;

AGED; ANTIFUNGAL AGENTS; CANDIDIASIS; COHORT STUDIES; CRITICAL ILLNESS; ECHINOCANDINS; FEMALE; FRANCE; HUMANS; INTENSIVE CARE UNITS; MALE; PROGRAM EVALUATION; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84904641760     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-385     Document Type: Article

References (30)

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535.
2. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012, 18(Suppl 7):19-37.
3. Schuster MG, Edwards JE, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Panzer H, Biswas P, Rex JH. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008, 149(2):83-90.
4. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43(1):25-31.
5. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49(9):3640-3645.
6. Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010, 65(8):1765-1770.
7. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007, 60(3):613-618.
8. Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, Clark NM. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2012, 67(3):707-714.
9. Horvath LL, Hospenthal DR, Murray CK, Dooley DP. Detection of simulated candidemia by the BACTEC 9240 system with plus aerobic/F and anaerobic/F blood culture bottles. J Clin Microbiol 2003, 41(10):4714-4717.
10. Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, Leon MA. A bedside scoring system (" Candida score" ) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34(3):730-737.
11. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, Balasini C, Utande-Vazquez A, de Molina FJ G, Blasco-Navalproto MA, Lopez MJ, Charles PE, Martin E, Hernandez-Viera MA. Usefulness of the " Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009, 37(5):1624-1633.
12. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007, 26(4):271-276.
13. Playford EG, Lipman J, Kabir M, McBryde ES, Nimmo GR, Lau A, Sorrell TC. Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med 2009, 35(12):2141-2145.
14. Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L, Hamidfar-Roy R, Cornet M, Timsit JF, Pelloux H. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother 2011, 66(12):2880-2886.
15. Blot S, Charles PE. Are we doing better? - Trends in incidence, diagnosis, and outcome. Minerva Anestesiol 2013, 79(12):1396-1405.
16. Lopez-Medrano F, San Juan R, Lizasoain M, Catalan M, Ferrari JM, Chaves F, Lumbreras C, Montejo JC, de Herreros Tejada A, Aguado JM. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect 2013, 19(1):56-61.
17. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22(7):707-710.
18. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012, 54(8):1110-1122.
19. Vach W. Regression Models as a Tool in Medical Research 2013, Boca Raton, FL: CRC Press, Taylor & Francis Group.
20. Kett DH, Azoulay E, Echeverria PM, Vincent JL, . Investigators EPoIitIsEIgo Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011, 39(4):665-670. Investigators EPoIitIsEIgo.
21. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl J-P, Francais A, Martin C, Guidet B, Timsit J-F. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med 2012, 40(3):813-822.
22. Charles PE. Multifocal Candida species colonization as a trigger for early antifungal therapy in critically ill patients: what about other risk factors for fungal infection?. Crit Care Med 2006, 34(3):913-914.
23. Leon C, Ruiz-Santana S, Saavedra P, Castro C, Ubeda A, Loza A, Martin-Mazuelos E, Blanco A, Jerez V, Ballus J, Alvarez-Rocha L, Utande-Vazquez A, Farinas O. Value of beta-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 2012, 38(8):1315-1325.
24. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1->3)-beta-D-glucan assay, Candida score, and colonization index. Crit Care 2011, 15(5):R249.
25. Clancy CJ, Nguyen MH. Finding the " missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013, 56(9):1284-1292.
26. Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, Shields RM, Cheng S, Mitsani D, Vadnerkar A, Silveira FP, Kleiboeker SB, Clancy CJ. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012, 54(9):1240-1248.
27. Takesue Y, Kakehashi M, Ohge H, Imamura Y, Murakami Y, Sasaki M, Morifuji M, Yokoyama Y, Kouyama M, Yokoyama T, Sueda T. Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004, 28(6):625-630.
28. Tissot F, Lamoth F, Hauser PM, Orasch C, Fluckiger U, Siegemund M, Zimmerli S, Calandra T, Bille J, Eggimann P, Marchetti O. Beta-glucan antigenemia anticipates diagnosis of blood culture-negative intra-abdominal candidiasis. Am J Respir Crit Care Med 2013, 188(9):1100-1109.
29. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004, 39(2):199-205.
30. Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR, Alexander BD. Beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012, 7(8):e42282.